Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,181 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05488522RecruitingPhase 1
Radiation plus immunotherapy for liver cancer
This early-phase trial tests a treatment plan that combines focused radiation with two medicines—an immunotherapy drug and an anti-angiogenesis drug—to treat hepatocellular carcinoma (liver cancer). It may help shrink tumors or control disease when surgery or ablation can’t be used, and when systemic (whole-body) treatment is needed.
Philadelphia, PennsylvaniaAges 18–99 - NCT05488548RecruitingPhase 1
Study drug that blocks BET and CBP/p300 in advanced cancers
This Phase 1 trial tests an investigational medicine that targets BET and CBP/p300 to try to slow or control advanced, hard-to-treat cancers. You may be eligible if you have certain prostate cancer or NUT midline carcinoma, or specific blood cancers like CMML or myelofibrosis (MF), and your body functions are strong enough for chemotherapy-style treatment.
Phoenix, ArizonaAges 18 years+ - NCT05489289RecruitingPhase 3
AK104 to prevent HCC coming back after surgery
This trial tests whether AK104, taken after liver cancer surgery, can lower the chance that the cancer returns. It is for people with high risk of recurrence but no remaining cancer after surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05491512RecruitingPhase 2
Reduced radiation with chemo for HPV throat cancer
This trial tests whether giving less radiation (while using standard chemotherapy) can treat HPV-related throat cancer effectively. It may help reduce radiation exposure while still controlling the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT05493566RecruitingEarly Phase 1
Low-dose IL-2 plus pembrolizumab for stage IV lung cancer
This early-phase study tests whether low-dose IL-2 combined with pembrolizumab can help treat stage IV non-small cell lung cancer that has not had prior advanced treatment. It may be an option if your tumor has certain immune-marker findings (PD-L1) and you meet safety requirements.
Atlanta, GeorgiaAges 18 years+ - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
La Jolla, CaliforniaAges 18 years+ - NCT05498064Recruiting
Study of ensartinib for advanced ALK-positive lung cancer
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05500391RecruitingPhase 2
Testing whether remote nurse monitoring works like in-person checks
This Phase 2 study compares two ways of checking your cancer follow-up: a doctor or nurse visits in person versus remote monitoring by phone and imaging. The goal is to see whether remote monitoring can safely replace or match in-person care for certain low-risk cancers and after surgery.
AmiensAges 18 years+ - NCT05501665RecruitingPhase 1/Phase 2
Adaptive radiation plus pembrolizumab for stage IV lung cancer
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
Nashville, TennesseeAges 18 years+ - NCT05502198Recruiting
How muscle loss matters in advanced liver disease
This study looks at how loss of muscle strength or mass (sarcopenia) relates to advanced liver disease. It may help doctors understand which patients are at higher risk and could guide future care choices.
EksjöAges 18 years+ - NCT05502523Recruiting
Blood test DNA levels after lung surgery
This study looks at how different lung surgical techniques affect levels of tumor DNA in the blood before and after surgery for early-stage lung cancer. It may help doctors choose surgical approaches and use a blood test to monitor cancer after surgery.
Abington, PennsylvaniaAges 18 years+ - NCT05507411RecruitingPhase 2
Watch-and-wait after chemo-radiation plus immunotherapy for esophagus cancer
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Hanzhou, ZhejiangAges 18–75 - NCT05514275RecruitingPhase 2
Radiation plus endostatin and capecitabine for nasopharyngeal cancer
This Phase 2 trial tests whether adding endostatin and capecitabine to standard radiation can improve outcomes for people with non-keratinizing nasopharyngeal cancer that has not responded well to chemotherapy. It may help those with stable or worsening disease after treatment before moving to radiation.
Hangzhou, ZhejiangAges 18–65 - NCT05518253RecruitingPhase 1
CAR-T treatment for CD70-positive advanced solid tumors
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hangzhou, ZhejiangAges 18 years+ - NCT05520788Recruiting
Genetic test-guided treatment for advanced bile and liver cancers
This study looks at using a genetic test (next-generation sequencing) to find cancer gene changes in stage IV hepatobiliary cancer. If there is a matching approved medicine, the study follows how well the “right drug for the right mutation” helps patients receiving palliative care.
Wuhan, HubeiAges 18 years+ - NCT05522881Recruiting
Study of genetic changes in oropharyngeal cancer tumors
This study collects information and tumor tissue to look for genetic changes in oropharyngeal cancer, especially in patients whose cancer has come back. The goal is to better understand the disease and may help future treatment planning.
Kaohsiung CityAges 20 years+ - NCT05525338RecruitingPhase 4
Test standard vs adjusted alectinib dose using blood levels
This trial compares the usual dose of alectinib with a modified dose chosen by checking alectinib blood levels. It aims to see whether adjusting the dose based on blood testing can work as well (and possibly be better tolerated) for people with ALK-positive non-small cell lung cancer.
Villejuif, Val-de-MarneAges 18 years+ - NCT05534906Recruiting
Detecting very early liver cancer and tracking its natural course
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
Oxford, OxfordshireAges 18–100 - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT05539638Recruiting
Testing blood DNA for head and neck squamous cancer
This study looks at how tumor DNA found in a blood sample (a “DNA signal”) relates to head and neck cancer in the oropharynx. It may help doctors understand disease status and improve how they monitor treatment, for both HPV-positive and HPV-negative cancers.
Dundee, DD2 1SGAges 18 years+ - NCT05541601Recruiting
Study to detect liver cancer early in people with cirrhosis
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
Oxford, OxfordshireAges 18–100 - NCT05542407RecruitingPhase 1
ONC201 plus atezolizumab for endometrial cancer and obesity
This Phase 1 study tests ONC201 together with atezolizumab in people with metastatic or returning endometrial cancer, especially when obesity may be driving the cancer. It aims to find a safe dose and see whether the combination can slow the cancer’s growth.
Chapel Hill, North CarolinaAges 18 years+ - NCT05557877RecruitingPhase 2
Low-dose aspirin to prevent postpartum breast cancer
This study tests whether taking a low dose of aspirin after childbirth can lower the chance of developing breast cancer later. You may be asked to provide blood, urine, and breast tissue samples so researchers can look for changes that could explain why aspirin may help.
Scottsdale, ArizonaAges 18–45
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,181 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.